NCT02677051Active, not recruitingPhase 2
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
Sulforaphane in Autism: A Treatment Trial to Confirm Phenotypic Improvement With Sulforaphane Treatment in a New Jersey (NJ) Population of Individuals With Autism
Source: ClinicalTrials.gov · Last updated 29 Oct 2025
Brief summary (registry, in English)
This study is a double blind treatment trial that will test if sulforaphane improves core symptoms in autism. The investigators expect to see clinical improvement in some of these areas. Sulforaphanes come from eating certain vegetables such as broccoli. The investigators will be using a preparation that gives specific and reproducible amounts. The investigators will also test specific chemicals and genes needed for sulforaphane usage to try to understand differences in response.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 28 Jan 2016
- Start date
- Feb 2016
- Primary completion date
- Dec 2025
- Lead sponsor
- Rutgers, The State University of New Jersey
- Diseases
- Autism
- NCT number
- NCT02677051
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 48
- From Feb 2016 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current infection or treatment with antibiotics.
- Chronic medical disorder (e.g., cardiovascular disease, stroke or diabetes) or major surgery within 3 months prior to enrollment.
Other illness
- Seizure within 2 years of screening,
- A diagnosis of autism spectrum disorder other than autistic disorder, for example, Asperger, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) etc.
Lab values
- Impaired renal function (serum creatinine\> 1.2 mg/dl).
Age
- Less than 13 years or more than 30 years of age.
Other
- Absence of a parent or legal guardian and consent,
- Those that can not or will not complete all visits and adherence to study regimen.
- Impaired hepatic function (\> 2x upper limit of normal).
- Impaired thyroid function (TSH outside normal limits).
- Female gender.
Who the study is looking for
- Autistic disorder diagnosis.
- Age between 13-30 years.
- Male gender.
Age in the registry: 13 years to 30 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rutgers University - Staged Research Building Coordinator of this site? Confirm its status | Piscataway | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.